Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.47 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31223199 | 1.00 | IDO1 (0.65) | IDO1MAOBHDAC1SMN1; SMN2HTT | |
| SCHEMBL147440 | 0.85 | IDO1 (0.65) | IDO1SMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL1137180 | 0.83 | MAOB (0.51) | IDO1MAOBSMN1; SMN2HTTMAPT | |
| SCHEMBL29142697 | 0.83 | TDP1 (0.51) | IDO1MAOBSMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL7659979 | 0.82 | HTT (0.54) | SMN1; SMN2HTTL3MBTL1MAPTMEN1 | |
| SCHEMBL30368269 | 0.82 | RAB9A (0.58) | IDO1HDAC1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL863069 | 0.82 | RAB9A (0.58) | IDO1HDAC1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL3931647 | 0.82 | SMN1; SMN2 (0.50) | IDO1MAOBSMN1; SMN2MAPTMEN1 | |
| SCHEMBL26931412 | 0.82 | MAPT (0.52) | IDO1MAOBSMN1; SMN2HTTGAA | |
| SCHEMBL8859862 | 0.81 | KIF11 (0.61) | IDO1MAOBGAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117940432-A | Camptothecins compound, preparation method and application thereof | 上海弼领生物技术有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-15 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20170197976-A1 | MTH1 INHIBITORS FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-07-13 | — | — | US | disclosed |
| CN-106794181-A | MTH1 inhibitors for the treatment of inflammatory and autoimmune conditions | 托马斯·黑勒戴药物研究基金会 | 2017-05-31 | — | — | CN | disclosed |
| EP-3151833-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| WO-2010052448-A2 | FUSED PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20060287356-A1 | dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders | IYENGAR RAJESH R | 2006-12-21 | — | — | US | disclosed |
| US-7119205-B2 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBOTT LABORATORIES (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
| EP-0530338-B1 | ANISOTROPIC ORGANIC COMPOUNDS | QINETIQ LTD (GB) | 2002-05-02 | — | — | EP | disclosed |
| US-5888421-A | LIQUID CRYSTALS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1999-03-30 | — | — | US | disclosed |
| WO-1992016519-A2 | ANISOTROPIC ORGANIC COMPOUNDS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179790-B2 | MTH1 inhibitors for treatment of cancer | MTHFD1, MTHFD2, DPYD | IDO1 2571/4885MAOB 3686/4885HDAC1 1116/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | IDO1 694/4885MAOB 3850/4885HDAC1 1787/4885 |
| US-20060287356-A1 | dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders | GPR119, FABP4, ADIPOR1 | IDO1 2976/4885MAOB 3529/4885HDAC1 792/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | IDO1 119/4885MAOB 553/4885HDAC1 110/4885 |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | PRKAG1, PRKAG3, PRKAG2 | IDO1 4236/4885MAOB 2458/4885HDAC1 865/4885 |
| US-20170197976-A1 | MTH1 INHIBITORS FOR TREATMENT OF CANCER | MTHFD1, MTHFD2, DPYD | IDO1 2571/4885MAOB 3686/4885HDAC1 1116/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | IDO1 694/4885MAOB 3850/4885HDAC1 1787/4885 |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | IDO1 694/4885MAOB 3850/4885HDAC1 1787/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | IDO1 694/4885MAOB 3850/4885HDAC1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.